Oncology Archives

June 2, 2018

Published by Preeti Parikh at June 2, 2018

Categories

Major Milestones In Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This video highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the […]

June 2, 2018

Published by Sakshi Saini at June 2, 2018

Categories

Top ASCO 2018 Abstracts To Watch Out For In Lymphoma

Abstract 7504: Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Conclusion: 5F9 + rituximab is a novel immunotherapy that inhibits a key macrophage/cancer checkpoint. It is well tolerated with no MTD reached and has promising clinical activity […]

June 2, 2018

Published by Sakshi Saini at June 2, 2018

Categories

Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers

Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the […]

September 12, 2017

Published by Zahid Nabi at September 12, 2017

Categories

Immuno-Oncology Therapies In Renal Cell Carcinoma

A quick overview on the I/O Therapies In Renal Cell Carcinoma

September 11, 2017

Published by Zahid Nabi at September 11, 2017

Categories

Oncology

Anti-PD1 and PD-L1 Agents in Development

Distribution of Anti Pd-1 / Anti PD-L1 by Phase

June 1, 2017

Published by Sakshi Saini at June 1, 2017

Categories

Journey through ASCO 2015 to 2017

In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be […]